Over six decades ago, we treated our first patient with lung disease. Today, our patients come from all over the United States to receive care from our adult and pediatric lung disease specialists. Why? State-of-the-art technology, the newest treatments and techniques, and clinical research are at work here every day to help extend and improve the quality of life for patients.
Diagnosing and Treating Lung Diseases
From more common lung diseases like pneumonia, asthma, and chronic obstructive pulmonary disease (COPD) to rare conditions like Alpha 1-antitrypsin deficiency and sarcoidosis — patients are in excellent hands here. UT Health is home to the largest team of physicians in Northeast Texas dedicated to diagnosing and treating lung diseases.
Conditions We Commonly Treat
- Lung Diseases
- Abnormal chest x-rays
- Alpha-1 antitrypsin deficiency
- Cancers of the chest (lung, chest wall, and cavity)
- Chronic bronchitis
- Chronic cough
- Chronic obstructive pulmonary disease (COPD)
- Chronic respiratory failure
- Cystic fibrosis
- Occupational lung disease
- Pulmonary embolism
- Pulmonary fibrosis
Experts in Diagnostic Testing
Behind every great physician caring for patients is a strong diagnostic testing team. This team consists of physicians and other health professionals experienced in laboratory testing, imaging, and other testing tools.
With the only pulmonary pathologist in our region — one of only 100 in the U.S. — our pathology services include state-of-the-art clinical and anatomical diagnostic testing as well as immediate, real-time evaluations.
Imaging tests including x-rays, computer tomography (CT scan), magnetic resonance imaging (MRI), and positron emission tomography (PET).
Pulmonary function testing, which measures how well the lungs take in and release air and how well they move gases such as oxygen from the atmosphere into the body’s circulation.
Newly identified bacteria, Nocardia wallacei, that cause infections like pneumonia, was named after Dr. Richard Wallace, a specialist at UT Health who is internationally recognized for researching and treating a rare but serious lung infection called mycobacterial avium complex (MAC).
Patient and Visitor Guide
To learn about helpful information, services, and amenities offered to patients and visitors, get the guide to UT Health.
A study assessing the safety and efficacy of weekly intravenous Alpha1-proteinase Inhibitor in patients with pulmonary emphysema due to Alpha1-antitrypsin deficiency.
A study evaluating the level of medication in the fluid of the lungs, the level of medication in the blood, and the safety of inhaled Alpha1-Antitrypsin in patients with Alpha1-Antitrypsin deficiency.
The purpose of this study is to find out how well Ciprofloxacin DPI works in delaying the occurrence of an exacerbation and in reducing the frequency of bronchiectasis exacerbations requiring treatment with antibiotics. Total length of participation in the study is approximately 48 weeks.
The purpose of the study is to evaluate the efficacy of AeroVanc in reducing the quantity of MRSA colony forming units (CFUs) in the sputum cultures of CF patients with persistent MRSA lung infection.
For more information, please contact:
Rebekah Steger, CCRC
The purpose of this study is to assess the safety and efficacy of BMS-986020 on the management of patients with IPF. Participation in the study will involve 14 visits over 26 weeks.
This is a study in adult and adolescent subjects with persistent asthma. The study consists of a total of 9 visits with total study duration of approximately 29 weeks
This is a study in subjects 4-11 years of age with persistent asthma. The study consists of a total of 10 visits with total study duration of approximately 6 months.
For more information, please contact: